Compare SWKH & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | NYXH |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 188.1M |
| IPO Year | 1999 | 2021 |
| Metric | SWKH | NYXH |
|---|---|---|
| Price | $17.04 | $4.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $12.67 |
| AVG Volume (30 Days) | 10.3K | ★ 56.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $40,149,000.00 | $6,616,215.00 |
| Revenue This Year | $52.93 | $79.25 |
| Revenue Next Year | N/A | $297.08 |
| P/E Ratio | $9.25 | ★ N/A |
| Revenue Growth | ★ 62.38 | 10.96 |
| 52 Week Low | $13.17 | $4.35 |
| 52 Week High | $20.49 | $11.87 |
| Indicator | SWKH | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 47.14 |
| Support Level | $16.69 | $4.60 |
| Resistance Level | $17.75 | $5.01 |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 55.24 | 71.67 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.